PL356402A1 - Kombinacja inhibitora wychwytu zwrotnego serotoniny i antagonisty, odwracalnego agonisty lub częściowego agonisty receptora 5-HT 2C - Google Patents

Kombinacja inhibitora wychwytu zwrotnego serotoniny i antagonisty, odwracalnego agonisty lub częściowego agonisty receptora 5-HT 2C

Info

Publication number
PL356402A1
PL356402A1 PL00356402A PL35640200A PL356402A1 PL 356402 A1 PL356402 A1 PL 356402A1 PL 00356402 A PL00356402 A PL 00356402A PL 35640200 A PL35640200 A PL 35640200A PL 356402 A1 PL356402 A1 PL 356402A1
Authority
PL
Poland
Prior art keywords
serotonin reuptake
ht2c
combination
compounds
reuptake inhibitor
Prior art date
Application number
PL00356402A
Other languages
English (en)
Inventor
Thomas Ivo Franciscus Hubert Cremers
Hakan Wilhelm Wikstrom
Boer Johan Antonie Den
Fokko Jan Bosker
Bernard Hendrik Cornelis Westerink
Klaus Peter Bogeso
Sandra Hogg
Arne Mork
Original Assignee
H.Lundbeck A/S
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by H.Lundbeck A/S filed Critical H.Lundbeck A/S
Publication of PL356402A1 publication Critical patent/PL356402A1/pl

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
    • G01N33/9406—Neurotransmitters
    • G01N33/942—Serotonin, i.e. 5-hydroxy-tryptamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/36—Arsenic; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
    • G01N33/9406—Neurotransmitters
    • G01N33/9413—Dopamine
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Psychiatry (AREA)
  • Inorganic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Addiction (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
PL00356402A 1999-12-06 2000-12-06 Kombinacja inhibitora wychwytu zwrotnego serotoniny i antagonisty, odwracalnego agonisty lub częściowego agonisty receptora 5-HT 2C PL356402A1 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US16924599P 1999-12-06 1999-12-06
PCT/DK2000/000671 WO2001041701A2 (en) 1999-12-06 2000-12-06 The combination of a serotonin reuptake inhibitor and a 5-ht2c antagonist, inverse agonist or partial agonist

Publications (1)

Publication Number Publication Date
PL356402A1 true PL356402A1 (pl) 2004-06-28

Family

ID=22614803

Family Applications (1)

Application Number Title Priority Date Filing Date
PL00356402A PL356402A1 (pl) 1999-12-06 2000-12-06 Kombinacja inhibitora wychwytu zwrotnego serotoniny i antagonisty, odwracalnego agonisty lub częściowego agonisty receptora 5-HT 2C

Country Status (33)

Country Link
US (4) US20020103249A1 (pl)
EP (2) EP2036564A1 (pl)
JP (1) JP2003516326A (pl)
KR (1) KR100832026B1 (pl)
CN (2) CN1433313A (pl)
AT (1) ATE314849T1 (pl)
AU (2) AU1850801A (pl)
BG (1) BG106895A (pl)
BR (1) BR0016385A (pl)
CA (1) CA2393470A1 (pl)
CO (1) CO5251409A1 (pl)
CY (1) CY1105014T1 (pl)
CZ (1) CZ20021961A3 (pl)
DE (1) DE60025398T2 (pl)
DK (1) DK1237553T3 (pl)
EA (1) EA006391B1 (pl)
ES (1) ES2255519T3 (pl)
HR (1) HRP20020527A2 (pl)
HU (1) HUP0203586A3 (pl)
IL (2) IL149994A0 (pl)
IS (1) IS2227B (pl)
ME (1) MEP6208A (pl)
MX (1) MXPA02005613A (pl)
NO (1) NO20022657L (pl)
NZ (1) NZ545907A (pl)
PL (1) PL356402A1 (pl)
PT (1) PT1237553E (pl)
SK (1) SK7962002A3 (pl)
TR (1) TR200201512T2 (pl)
UA (1) UA77650C2 (pl)
WO (2) WO2001041766A1 (pl)
YU (1) YU41902A (pl)
ZA (1) ZA200204391B (pl)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR021155A1 (es) * 1999-07-08 2002-06-12 Lundbeck & Co As H Tratamiento de desordenes neuroticos
GB0005477D0 (en) 2000-03-07 2000-04-26 Resolution Chemicals Limited Process for the preparation of citalopram
US6589996B2 (en) 2000-03-17 2003-07-08 Orion Corporation Treatment of disorders relating to the serotonergic system
FI20002612A0 (fi) * 2000-11-28 2000-11-28 Orion Yhtymae Oyj Yhdistelmäterapia serotoniinivälityksen häiriöiden hoitamiseksi
WO2002043727A1 (en) * 2000-11-28 2002-06-06 Orion Corporation Treatment of psychiatric disorders with trimethyl-bicyclo[2.2.1]heptane derivatives
US6335371B1 (en) * 2000-11-28 2002-01-01 Orion Corporation Method for inducing cognition enhancement
US6335372B1 (en) * 2000-11-28 2002-01-01 Orion Corporation Treatment of obsessive compulsive disorder
WO2002087566A1 (en) * 2001-05-01 2002-11-07 H. Lundbeck A/S The use of enantiomeric pure escitalopram
GB0118892D0 (en) * 2001-08-02 2001-09-26 Vernalis Res Ltd Method of treatment
SE0201544D0 (sv) * 2002-05-17 2002-05-17 Biovitrum Ab Novel compounds and thier use
EP2260844A1 (en) * 2003-05-27 2010-12-15 Merz Pharma GmbH & Co. KGaA Combination of an NMDA Receptor Antagonist and a Selective Serotonin Reuptake Inhibitor for the Treatment of Depression and other Mood Disorders
US20050234093A1 (en) * 2003-06-25 2005-10-20 H. Lundbeck A/S Treatment of depression and other affective disorders
AR047553A1 (es) * 2003-07-04 2006-01-25 Lundbeck & Co As H La combinacion de un inhibidor de reabsorcion de serotonina y agomelatina
EP1500391A1 (en) * 2003-07-24 2005-01-26 Neuro3D Therapeutic use of bicycloheptane derivatives
ES2319539T3 (es) 2003-09-17 2009-05-08 Janssen Pharmaceutica Nv Compuestos heterociclicos condensados como moduladores del receptor de serotonina.
EP1708790B1 (en) * 2003-12-02 2010-04-21 PharmaNeuroBoost N.V. Use of pipamperone and a d2-receptor antagonist or a serotonin/dopamin antagonist for the treatment of psychotic disorders
US20050203130A1 (en) * 2003-12-02 2005-09-15 Erik Buntinx Use of D4 and 5-HT2A antagonists, inverse agonists or partial agonists
US7884096B2 (en) 2003-12-02 2011-02-08 Pharmaneuroboost N.V. Method of treating mental disorders using of D4 and 5-HT2A antagonists, inverse agonists or partial agonists
EP1713486A4 (en) * 2003-12-02 2009-04-29 Sheldon Leslie James COMBINED THERAPY FOR THE TREATMENT OF DEMENTIA, DEPRESSION AND APATHY
US7855195B2 (en) 2003-12-02 2010-12-21 Pharmaneuroboost N.V. Method of treating mental disorders using D4 and 5-HT2A antagonists, inverse agonists or partial agonists
US20050241110A1 (en) * 2004-04-09 2005-11-03 Bruce Baker Ergonomic handles, especially for garden tools
US7598255B2 (en) 2005-08-04 2009-10-06 Janssen Pharmaceutica Nv Pyrimidine compounds as serotonin receptor modulators
EP1996948A1 (en) * 2006-03-22 2008-12-03 H.Lundbeck A/S Method for identifying compounds for the treatment of depression
PL2044043T5 (pl) 2006-06-16 2022-05-02 H. Lundbeck A/S Bromowodorek 1-[2-(2,4-dimetylofenylosulfanylo)fenylo]piperazyny jako związek o połączonym działaniu wychwytu zwrotnego serotoniny i działaniu na 5-ht3 i 5-ht1a do leczenia upośledzenia funckji poznawczych
US20080081067A1 (en) * 2006-10-03 2008-04-03 Gupta Manishkumar Sustained release pharmaceutical compositions of venlafaxine and process for preparation thereof
US20090036468A1 (en) * 2007-08-03 2009-02-05 Forest Laboratories Holdings Limited Pharmaceutical compositions containing dopamine receptor ligands and methods of treatment using dopamine receptor ligands
JP2011507835A (ja) 2007-12-21 2011-03-10 アンドレイ・アレクサンドロビッチ・イワシェンコ α−アドレナリン受容体、ドーパミン、ヒスタミン、イミダゾリン及びセロトニン受容体のリガンド並びにその使用
WO2010006231A1 (en) * 2008-07-10 2010-01-14 Ore Pharmaceuticals Inc. Treating inflammation and related conditions with irindalone
AU2011277426B2 (en) 2010-07-15 2015-04-23 Sumitomo Pharma Co., Ltd. Pyrazole compound
EP2629615B1 (en) 2010-10-22 2018-10-10 Duke University Slow-release formulations of 5-hydroxytryptophan as an adjunct to pro-serotonergic therapies
WO2013119800A1 (en) 2012-02-07 2013-08-15 Massachusetts Institute Of Technology Use of antagonists of ghrelin or ghrelin receptor to prevent or treat stress-sensitive psychiatric illness
WO2014046544A1 (en) 2012-09-21 2014-03-27 Aapa B.V. Substituted 3-heteroaryloxy-3-(hetero)aryl-propylamines as serotonin transporter and serotonin ht2c receptor modulators
US9724396B2 (en) 2013-03-15 2017-08-08 Massachusetts Institute Of Technology Use of antagonists of growth hormone or growth hormone receptor to prevent or treat stress-sensitive psychiatric illness
US10317418B2 (en) 2015-02-24 2019-06-11 Massachusetts Institute Of Technology Use of ghrelin or functional ghrelin receptor agonists to prevent and treat stress-sensitive psychiatric illness
US20170007618A1 (en) * 2015-06-17 2017-01-12 Massachusetts Institute Of Technology Serotonin 2c receptor antagonists to prevent and treat stress-related trauma disorders
CN107556206A (zh) * 2016-06-30 2018-01-09 陕西合成药业股份有限公司 一种新型5‑羟色胺再摄取抑制剂类化合物及其制备方法和在医学上的应用
US11478467B2 (en) 2017-05-04 2022-10-25 Sreenivasarao Vepachedu Targeted drug rescue with novel compositions, combinations, and methods thereof
CN119470729B (zh) * 2025-01-15 2025-04-29 山东英盛生物技术有限公司 一种高效液相色谱-串联质谱法定量检测微量血液中霉酚酸的方法

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8814057D0 (en) * 1988-06-14 1988-07-20 Lundbeck & Co As H New enantiomers & their isolation
US5155218A (en) * 1990-05-08 1992-10-13 Neurogenetic Corporation Dna encoding human 5-ht1d receptors
EP0656003A1 (en) 1992-08-20 1995-06-07 Smithkline Beecham Plc Condensed indole derivatives as 5ht2c and 5ht2b antagonists
WO1994014801A1 (en) 1992-12-29 1994-07-07 Smithkline Beecham Plc Heterocyclic urea derivatives as 5ht2c and 5ht2b antagonists
US5521180A (en) * 1993-02-10 1996-05-28 Yamanouchi Pharmaceutical Co., Ltd. Morpholine derivative
GB9313913D0 (en) 1993-07-06 1993-08-18 Smithkline Beecham Plc Novel compounds
CA2134038C (en) * 1994-06-16 1997-06-03 David Taiwai Wong Potentiation of drug response
FI970310L (fi) * 1994-07-26 1997-01-24 Pfizer 4-indolijohdannaiset serotoniinin vaikuttaja- ja vastavaikuttaja-aineina
US5597826A (en) 1994-09-14 1997-01-28 Pfizer Inc. Compositions containing sertraline and a 5-HT1D receptor agonist or antagonist
GB9420999D0 (en) 1994-10-18 1994-12-07 Smithkline Beecham Plc Novel compounds
EP0714663A3 (en) * 1994-11-28 1997-01-15 Lilly Co Eli Potentiation of drug responses by serotonin 1A receptor antagonists
EP0807104A2 (en) 1995-02-02 1997-11-19 Smithkline Beecham Plc Heterocyclic compounds possessing 5ht 2c? receptor antagonist activity
SE9501567D0 (sv) * 1995-04-27 1995-04-27 Astra Ab A new combination
GB9511355D0 (en) 1995-06-06 1995-08-02 Fujisawa Pharmaceutical Co Urea derivatives
GB9514384D0 (en) * 1995-07-13 1995-09-13 American Home Prod Medical treatment
GB9517559D0 (en) 1995-08-26 1995-10-25 Smithkline Beecham Plc Novel compounds
FR2744449B1 (fr) 1996-02-02 1998-04-24 Pf Medicament Nouvelles piperazines aromatiques derivees de cycloazanes substitues, ainsi que leur procede de preparation, les compositions pharmaceutiques et leur utilisation comme medicaments
GB9607219D0 (en) 1996-04-04 1996-06-12 Smithkline Beecham Plc Novel compounds
CN1082963C (zh) 1996-04-12 2002-04-17 詹森药业有限公司 异噁唑烷衍生物
EP0813873B1 (en) * 1996-06-19 2002-02-13 Akzo Nobel N.V. Pharmaceutical composition comprising mirtazapine and one or more selective serotonin reuptake inhibitors
US5958429A (en) * 1996-08-16 1999-09-28 Eli Lilly And Company Potentiation of serotonin response
SE9703375D0 (sv) * 1997-09-18 1997-09-18 Astra Ab A new combination
HUP0101901A3 (en) * 1998-05-22 2002-06-28 Lilly Co Eli Pharmaceutical composition for combined therapeutic treatment of refractory depression and combined treating process
US6960577B2 (en) * 1998-05-22 2005-11-01 Eli Lilly And Company Combination therapy for treatment of refractory depression
BR9911068A (pt) * 1998-05-29 2001-02-06 Lilly Co Eli Terapia combinada para tratamento de distúrbios bipolares
DE19827750C1 (de) * 1998-06-22 1999-07-29 Centeon Pharma Gmbh Verfahren zum Abtrennen von HIV aus einer Flüssigkeit
DE19900673A1 (de) * 1999-01-11 2000-07-13 Basf Ag Verwendung von Bindungspartnern für 5-HT5-Rezeptoren zur Behandlung neurodegenerativer und neuropsychiatrischer Störungen
US20070259952A1 (en) * 2006-05-02 2007-11-08 H. Lundbeck A/S Uses of escitalopram

Also Published As

Publication number Publication date
DE60025398T2 (de) 2006-08-03
IL149994A0 (en) 2002-12-01
DE60025398D1 (de) 2006-03-30
JP2003516326A (ja) 2003-05-13
CZ20021961A3 (cs) 2002-11-13
NO20022657D0 (no) 2002-06-05
EP1237553A2 (en) 2002-09-11
KR20020060987A (ko) 2002-07-19
TR200201512T2 (tr) 2002-09-23
ATE314849T1 (de) 2006-02-15
YU41902A (sh) 2005-06-10
EA200200649A1 (ru) 2002-12-26
UA77650C2 (en) 2007-01-15
ZA200204391B (en) 2003-11-26
IL149994A (en) 2007-07-24
CN101406465A (zh) 2009-04-15
HRP20020527A2 (en) 2004-12-31
US20070105843A1 (en) 2007-05-10
ES2255519T3 (es) 2006-07-01
CO5251409A1 (es) 2003-02-28
EA006391B1 (ru) 2005-12-29
SK7962002A3 (en) 2002-09-10
PT1237553E (pt) 2006-05-31
WO2001041701A2 (en) 2001-06-14
HUP0203586A3 (en) 2005-02-28
CA2393470A1 (en) 2001-06-14
US20030032636A1 (en) 2003-02-13
US20090176808A1 (en) 2009-07-09
NZ545907A (en) 2007-07-27
WO2001041701A3 (en) 2001-12-13
IS2227B (is) 2007-04-15
HUP0203586A2 (hu) 2003-03-28
EP1237553B1 (en) 2006-01-04
EP2036564A1 (en) 2009-03-18
NO20022657L (no) 2002-07-26
MXPA02005613A (es) 2002-12-13
AU1851101A (en) 2001-06-18
MEP6208A (en) 2010-02-10
CN1433313A (zh) 2003-07-30
WO2001041766A1 (en) 2001-06-14
IS6404A (is) 2002-05-31
US20020103249A1 (en) 2002-08-01
DK1237553T3 (da) 2006-05-15
BR0016385A (pt) 2003-02-18
BG106895A (bg) 2003-04-30
CY1105014T1 (el) 2009-11-04
AU1850801A (en) 2001-06-18
KR100832026B1 (ko) 2008-05-23

Similar Documents

Publication Publication Date Title
PL356402A1 (pl) Kombinacja inhibitora wychwytu zwrotnego serotoniny i antagonisty, odwracalnego agonisty lub częściowego agonisty receptora 5-HT 2C
MXPA04005456A (es) Derivados de acetileno que tienen actividad antagonistica de mglur5.
AR020345A1 (es) Pirazol-carboxanilidas, procedimiento para su obtencion, composiciones, empleo de dichos compuestos y procedimiento para la lucha contra microorganismos indeseables, y procedimiento para la obtencion de dichas composiciones.
MY134110A (en) Combinations of reboxetine and neuroleptic agents
EP1399414A4 (en) SUBSTITUTED TETRACYCLINE COMPOUNDS FOR THE TREATMENT OF MALARIA
GB0111186D0 (en) Novel compounds
DE60324544D1 (de) Muskarin antagonisten
MXPA03009750A (es) Compuestos quimicos.
IL142900A0 (en) Compositions and methods for the prevention or treatment of cancer and bone loss associated with cancer
SI1562936T1 (sl) Terapevtske piperazinske spojine
MY120976A (en) 2-amino-6-(2-substituted-4-phenoxy)- substituted- pyridines
IL153147A0 (en) Phospholipid derivatives of valporic acid and mixtures thereof
DE60233350D1 (de) IMIDAZOi2,1-B -1,3,4-THIADIAZOLE SULFONAMIDES
BG105710A (en) 5ht1 antagonists for antidepressant therapy
ATE252833T1 (de) Biozidzusammensetzung und diese verwendendes sterilisationsverfahren
DE60101639D1 (de) Ein (1'R,2'S,5'R)-3-l-Menthoxypropan-1-ol, das eine kühlende Empfindung erzeugt
MXPA03007653A (es) Uso de lp82 para tratar trastornos hematopoyeticos.
BR9904075A (pt) Cetonas
YU37101A (sh) Proces za pripremanje n,n'-bis(2,3- dihidroksipropil)-5-((hidroksiacetil)metilamino)-2,4,6-trijodo-1,3- benzendikarboksamida
DE60201074D1 (en) Pyrazolopyridinderivate
WO2003051291A3 (en) Substituted 5-hydroxy-indole compounds for the treatment of glaucoma
EP1396267A3 (en) The combination of a serotonin reuptake inhibitor and a 5-HT2C antagonist, inverse agonist or partial agonist
MXPA04006085A (es) Compuestos de isocromano para el tratamiento de trastornos del sistema nervioso central.
UA85198C2 (ru) Производные морфолина как ингибиторы повторного поглощения норэпинефрина
MXPA02010837A (es) Compuestos derivados del felbamato.

Legal Events

Date Code Title Description
REFS Decisions on refusal to grant patents (taken after the publication of the particulars of the applications)